An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Their experiments showed outstanding antiviral performance, managing to completely inactivate HIV with a single guide RNA and ...

and recently published in the Journal of Virology that some of the excised viral DNA molecules form stable DNA circles that can reintegrate into the genome. 3 This phenomenon may pose a challenge to ...

Integrase is responsible for inserting viral genomic DNA into the host chromosome ... bind to the CD4 receptor on T-cells. They prevent the HIV gp120 protein from changing its shape to engage with ...

A study by McMichael and colleagues describes the earliest CD8 + T cell responses to transmitted HIV-1 and shows that ... induce escape mutations in the viral genome. By sequencing the virus ...

SaCas9 showed outstanding antiviral performance, managing to completely inactivate HIV with a single guide RNA (gRNA) and excise (cut out) the viral DNA with two gRNAs. The strategy of minimizing ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

For instance, Merck's (Whitehouse Station, NJ, USA) Isentress (raltegravir), a small-molecule inhibitor of the HIV integrase, the molecule that facilitates integration of the viral genome into the ...

such as HIV, encode additional trans-regulating factors or contain cis-regulating elements, thereby influencing the type and amount of transcribed RNA. The whole viral genome is transcribed and ...

A year later, his plasma viral load, HIV RNA and DNA in peripheral blood cells and HIV-specific CD4 and CD8 T-cell responses were undetectable and his HIV antibody levels were low, so he stopped ...